Digest Réseau Comment ça marche
Réseau
/
Sociétés
F.
Non vérifié

F. Hoffmann-La Roche Ltd

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiquePublicité/Marketing/Médias/Communication

106 communiqués de presse

Voir tous les communiqués de presse
08/12/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
08/12/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
08/12/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
08/12/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
01/12/2025
Industrie pharmaceutique
Annonces Économiques
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
18/11/2025
Industrie pharmaceutique
Annonces Économiques
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
17/11/2025
Industrie pharmaceutique
Annonces Économiques
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
09/11/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
03/11/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
02/11/2025
Industrie pharmaceutique
Annonces Économiques
Publicité/Marketing/Médias/Communication
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Source
F. Hoffmann-La Roche Ltd
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0